MBRX - Moleculin to conduct in vitro for WP1096 in COVID-19 shares up 2%

Moleculin Biotech ([[MBRX]] +2.3%) says that its research team has discovered a molecule WP1096 within its portfolio of antimetabolites that exhibit vitro antiviral activity against SARS-CoV.The independent laboratory testing of the antiviral activity of its WP1096 portfolio in a COVID-19 has demonstrated a therapeutic index of greater than 10, which is considered an industry-standard commercialization threshold for in vitro performance of antiviral drugs."This was an unexpected discovery and one that really demands an adaptive change in development strategy on our part. While we continue our preclinical development work on WP1122, including in vivo testing for SARS-CoV-2, we are now expanding our program by adding these two new molecules as well," says Walter Klemp, Chairman and CEO of Moleculin.The final data readout of WP1122 & WP1096 will push the estimated window for filing an Investigational New Drug application into 2021.

For further details see:

Moleculin to conduct in vitro for WP1096 in COVID-19, shares up 2%